This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack — the drugmaker accused two of the companies of engaging in the corporate practice of medicine. To date, Lilly and its rival, Novo Nordisk, have filed dozens of suits against numerous companies involved in compounding versions of semaglutide and tirzepatide, the obesity and diabetes drugs known as
New Phase III data has demonstrated the potential benefit of the monoclonal antibody obinutuzumab to treat lupus nephritis. This therapy is already approved for B cell malignancies. The REGENCY Phase III clinical trial evaluated 271 adults with active lupus nephritis, a severe complication of lupus that inhibits kidney function. Participants were randomised to receive either obinutuzumab plus mycophenolate mofetil and glucocorticoids as standard therapy, or a placebo plus standard therapy.
Indias pharma and healthcare sector recorded 71 deals amounting to USD 2.6 billion in Q1 2025, according to the Grant Thornton Bharat Pharma & Healthcare Dealtracker. While this marks a 5 per cent decline in deal volume and a 69 per cent drop in deal value compared to Q4 2024, the report notes continued investor interest. Mergers and acquisitions (M&A) accounted for 57 per cent of the total deal value, while private equity (PE) made up 59 per cent of the overall deal volume.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
The Royal Pharmaceutical Society (RPS) is recruiting for a new director for England after previous postholder Dr James Davies left the role at the end of last year. Applicants for the 80,000-85,000 director for England role must be a pharmacist, an RPS member, and have experience or knowledge of more than one sector in pharmacy […] The post New leadership role created at RPS as director for England sought appeared first on The Pharmacist.
Imagine a clinical trial with sedentary, overweight adults. One group is assigned to remain sedentary, the other to undergo intensive physical training with daily runs, calisthenics, and sports. After a week or two, the training group would probably feel sore and tired, and their endurance might be reduced. But we wouldn’t conclude that physical activity is bad for health.
361
361
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Imagine a clinical trial with sedentary, overweight adults. One group is assigned to remain sedentary, the other to undergo intensive physical training with daily runs, calisthenics, and sports. After a week or two, the training group would probably feel sore and tired, and their endurance might be reduced. But we wouldn’t conclude that physical activity is bad for health.
For the first time in over ten years, the US Food and Drug Administration (FDA) has approved a new targeted treatment for chronic spontaneous urticaria. Sanofi and Regeneron Pharmaceuticals collaborated to develop Dupixent (dupilumab). Under the FDA’s new authorisation, the therapy is indicated for individuals aged 12 years and over with the chronic inflammatory skin disease, who still experience symptoms despite taking histamine-1 (H1) antihistamine medication.
Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Tolvaptan Tablets in strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. The approved product is bioequivalent to Jynarque Tablets of the same strengths, originally developed by Otsuka Pharmaceutical Company Lupin is the exclusive first-to-file applicant for this product, making it eligible for 180 days of generic drug exclusivity in the United States.
The government has launched a call for evidence to support its Mens Health Strategy, which was announced last year and is the first of its kind. Health professionals are among those being asked for ideas and evidence to the unique challenges men face throughout their lives. The strategyis being developed to tackle stark inequalities in […] The post Government seeks pharmacists' views to underpin first-ever mens health strategy appeared first on The Pharmacist.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
High blood pressure earned its reputation as the silent killer by causing heart attacks, heart failure, and strokes. It’s also been a suspect in dementia. Some studies have hinted at a correlation between lower blood pressure and fewer dementia cases, but they were too small and too short to lend statistical significance to the link. It’s also been noted that people with untreated high blood pressure carry a 42% higher risk of developing dementia.
By John W.M. Claud & Michelle L. Butler Recent reductions in force (RIFs) and leadership changes at FDA are already affecting key agency functionsand as the administration plans a broader reorganization, the impact will likely grow. One area drawing increasing attention is how these changes will affect the drug development and review process. As reported by the Wall Street Journal last week , reviews of both innovative and follow-on drugs have been caught in a traffic jam, largely due to a
ENTOD Pharmaceuticals has announced that it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for a new ophthalmic formulation designed to slow the progression of myopia in children aged 6 to 12 years. This marks the first global regulatory approval for this specific treatment strength in paediatric eye care.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Two clinical-stage oncology programmes from Astex Pharmaceuticals have been announced by Mosaic Therapeutics, allowing it to develop targeted oncology drug combinations. This elevates the research and platform company to a clinical-stage oncology business, bringing products closer to commercialisation and market access. Mosaic now has exclusive rights to develop its combination products in these trials.
Some key public health figures are taking an extraordinary step to try to shore up U.S. vaccination policy, feared to be under threat from Health and Human Services Secretary Robert F. Kennedy Jr., a longtime vaccine critic. The “Vaccine Integrity Project,” which was publicly launched Thursday by the University of Minnesota’s Center for Infectious Disease Research and Policy, will be aimed at assessing the best ways for vaccine proponents to safeguard vaccination policy and
SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.
"Patent Expiration: The $1.4 Trillion Wake-Up Call for the Pharmaceutical Industry As the pharmaceutical landscape continues to shift, one thing is clear: the expiration of drug patents is no longer a footnote in the industry's financials. According to a recent analysis, the loss of exclusivity for top-selling medications will result in a staggering $1.4 trillion in lost revenue by 2025.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
As monoclonal antibody (mAb) therapies and biosimilars reshape the global biologics landscape with the mAbs market expected to grow from USD 233.19 billion in 2024 to reach around USD 919.06 billion by 2033 [1] Cytiva announced the launch of two advanced protein A chromatography resins: MabSelect SuRe 70 and MabSelect PrismA X. Developed to meet the evolving purification demands of biopharma innovators, these next-generation resins deliver enhanced productivity, durability, and affordability ac
Galapagos NV has announced key leadership changes as it prepares to separate into two independent entities. Henry Gosebruch has been appointed founding CEO of the newly created subsidiary, currently named SpinCo. The subsidiary, which will operate independently following the split, is funded by Galapagos. Gosebruch joins SpinCo with extensive experience in business development and mergers […] The post Galapagos announces leadership changes amid planned company split appeared first on Pharm
The young people who wanted to quit e-cigarettes didn’t necessarily think they were addicted. But they did think nicotine cravings were a problem. When they enrolled in a Massachusetts General Hospital trial, they told researchers they couldn’t study in the library or work at their desks for long before getting the urge to vape. “They really didn’t like that loss of control,” said Eden Evins, director of the addiction center at Mass General.
Introduction Pharma brands are rethinking their digital engagement strategies in 2025. With regulatory scrutiny evolving and audience expectations shifting, social media marketing plans have become a central focus for companies looking to maintain trust while expanding reach. Social platforms are no longer just optional toolsthey’re vital channels for HCP and patient engagement.
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
The largest clinical trial investigating a treatment for bronchiectasis has demonstrated a statistically significant reduction in the occurrence of pulmonary exacerbations.Findings from the Phase III ASPEN study of brensocatib could provide future promise for patients, as there are currently no approved treatments for the chronic inflammatory pulmonary disease.
Disease overview Cholestatic liver disease is a condition that causes liver damage and fibrosis due to bile stasis. It is characterized by the slowing or stalling of bile flow through the hepato-biliary system (liver and bile duct). When bile flow is affected, it backs up into the organs and bloodstream, caus- ing inflammation. The disease is represented by primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), but the pathophysiological pathways that cause bile stasis in bo
Flemish biopharma company, Bioxodes, has announced promising results from the BIRCH phase 2a clinical trial of BIOX-101 to treat intracerebral haemorrhagic stroke (ICH). This brings the company closer to rolling out the first approved treatment for the devastating condition. The BIRCH trial, which took place with 16 patients with ICH, met both primary safety and […] The post Successful clinical outcomes for drug treating rare stroke condition appeared first on Pharmafile.
The federal health department is not creating a new registry of Americans with autism, a Department of Health and Human Services official said in a written statement Thursday. Instead, the official said, HHS will launch a $50 million research effort to understand the causes of autism spectrum disorder and improve treatments. The announcement arrives two days after National Institutes of Health Director Jay Bhattacharya announced the intent to create such a registry at an all staff meeting, kicki
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Almost five million Pharmacy First consultations were delivered in the first year of the service in England, official data has confirmed. The latest data from the NHS Business Services Authority (NHSBSA) shows that contractors in England submitted claims for 4,941,308 Pharmacy First consultations between February 2024 and January 2025. Of those, more than half (2,735,577) […] The post Almost five million Pharmacy First consultations delivered in first year appeared first on The Pharmacist.
Introduction In a rapidly evolving healthcare landscape, how can your Pharma Network stay ahead of the curve? As pharmaceutical brands face an unprecedented wave of digital transformation, strategic innovation, and shifting regulatory landscapes in 2025, optimizing your network has never been more critical. Much like upgrading an outdated GPS for an unknown journey, refreshing your pharma connections will determine whether your brand thrives or struggles in the new era.
On the occasion of AML World Awareness Day, AbbVie, a global biopharmaceutical company, announced the launch of Venetoclax in India for the treatment of Acute Myeloid Leukaemia (AML) and Chronic Lymphocytic Leukaemia (CLL). This marks AbbVies entry into the Indian oncology market. AML is a type of blood cancer that progresses rapidly and affects the blood and bone marrow.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
358 
Let's personalize your content